See The Pharma Letter to learn more about a recent deal where AbbVie licensed biosimilar adalimumab to Pfizer. Under the deal terms, AbbVie will grant Pfizer a non-exclusive license on specified dates to AbbVie’s intellectual property relating to TNF inhibitor Humira (adalimumab) in the USA and in various countries around the world in which AbbVie has intellectual property.

Source: The Pharma Letter

Pin It on Pinterest